WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005117550) COMPOSITION AND METHOD FOR THE TREATMENT OF TAUOPATHIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/117550    International Application No.:    PCT/US2005/018640
Publication Date: 15.12.2005 International Filing Date: 26.05.2005
IPC:
A01N 43/04 (2006.01), A61K 31/70 (2006.01)
Applicants: TAUTATIS, INC. [US/US]; c/o Argil Management, 124 Mt. Auburn Street, Suite 200N, Cambridge, MA 02138 (US) (For All Designated States Except US).
RODER, Hanno [DE/US]; (US) (For US Only)
Inventors: RODER, Hanno; (US)
Agent: MORENCY, Michel; Foley & Lardner, LLP, 111 Huntington Avenue, Boston, MA 02199 (US)
Priority Data:
10 2004 025 726.4 26.05.2004 DE
Title (EN) COMPOSITION AND METHOD FOR THE TREATMENT OF TAUOPATHIES
(FR) COMPOSITION ET PROCEDE DE TRAITEMENT DE TAUOPATHIES
Abstract: front page image
(EN)The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurodegenerative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
(FR)L'invention concerne l'utilisation d'un composé d'indolocarbazole spécifique, de formule générale (1) ou d'un sel pharmaceutiquement acceptable de celui-ci, pour la préparation d'une composition pharmaceutique destinée à la prévention ou au traitement de maladies neurodégénérescentes et/ou de démences provoquées par la pathologie moléculaire de tau associé à des microtubules, telles que maladie d'Alzheimer, démence du lobe frontal, maladie de Pick, maladie de Parkinson avec démence, dégénérescence corticobasale, argyrophilie granulaire, ou paralysie supranucléaire. L'invention concerne en outre un procédé de traitement ou de prévention de telles maladies. Par ailleurs, l'invention concerne des procédés d'identification d'inhibiteurs efficaces de dégénérescence neurofibrillaire, ainsi que des procédés de détermination d'un dosage approprié d'un inhibiteur d'hyperphosphorylation de tau du type PHF, pour le traitement d'un état caractérisé par une pathologie neurofibrillaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)